Pfenex Inc

Team Pfenex Inc donating personal protective equipment to our healthcare workers on the front lines of #covid19 at Sharp Memorial Hospital. So proud to be a part of this team doing what we can to help out. #PfenexStrong #WeAreInThisTogether

On March 11 following market close, Pfenex will host a conference call/webcast to discuss its fourth quarter and full year 2019 financial results. For more information, including phone numbers, visit the link below. URL : http://pfenex.investorroom.com/news-releases?item=169 #PFNX

Pfenex is thrilled to be making an impact on global health with our protein production platform. The Serum Institute of India achieved World Health Organization (WHO) prequalification for Pneumosil, a pneumococcal vaccine for low and middle- income countries using our carrier protein CRM197. http://pfenex.investorroom.com/news-releases?item=168

We’re pleased to announce that Pfenex has earned a $15 million development milestone under the development and license agreement with Jazz Pharmaceuticals. This just further validates the impact the Pfenex platform and capabilities can have on expediting product development. https://bit.ly/2r9q7fE

Pfenex is looking forward to Antibody Engineering & Therapeutics, Dec 9-13 in San Diego. Following our first FDA approval in October for a product made via the Pfenex Expression Technology, Cory Schwartz from Pfenex will present a poster on the efficient production of Ab derivatives. https://bit.ly/2RiHNjH

Catch President and Chief Executive Officer, Eef Schimmelpennink, at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4th. Following the recent US FDA approval of PF708 he will be sharing some great news about the progress and plans for Pfnex Inc. For those that can’t attend, be sure to stream the live audio webcast on our website. #PFNX $PFNX https://bit.ly/2XIyLxw

Make sure you catch our President and Chief Executive Officer, Eef Schimmelpennink, at this year’s Evercore ISI HealthCONx Conference on December 3rd. He will be presenting on Pfenex’s progress and future plans utilizing the Pfenex Expression Technology platform. You can also access the live audio webcast on our website. #PFNX $PFNX

We’re proud of the results we achieved during the third quarter of this year including our FDA approval for PF708, the first approved drug developed in our Pfenex Expression Technology platform. Please read our results to learn more including our new portfolio opportunities. https://bit.ly/2NNTiMB

We’re proud to announce Eef Schimmelpennink, our President and Chief Executive Officer, will be presenting at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20th at the Waldorf Hilton in London. Join the live audio webcast 4:00 p.m. GMT (8:00 a.m. PST). #pfnx

We believe the third quarter of this year has marked another successful one for Pfenex, Inc. Make sure you tune in on November 7, 2019, at 4:30pm Eastern Time/1:30pm Pacific Time, as we provide a business update and review of the third quarter financial results. https://bit.ly/2PgyyiT

Did you know 1 in 3 women over 50 will suffer a fracture due to osteoporosis? October 20th is World Osteoporosis Day, highlighting the importance of bone health and treatment. Pfenex Inc's PF708 (teriparatide), a therapeutic equivalent to Forteo, can help at-risk women and men increase bone mineral density. Learn more about PF708 at https://bit.ly/2J358Rb

Today we celebrate a momentous milestone in Pfenex’s history, the US FDA has approved the new drug application (NDA) for PF708 submitted via the 505(b)(2) regulatory pathway with Forteo (teriparatide injection) as the reference drug. This approval marks a major milestone in Pfenex’s history as our first approved commercial product and further validates our Pfnex Expression Technology platform for the development of therapeutic proteins. #PFNX #osteoporosis http://pfenex.investorroom.com/news-releases?item=157